Beam Therapeutics Inc (BEAM)
34.03
+1.52
(+4.68%)
USD |
NASDAQ |
Jun 02, 16:00
34.23
+0.20
(+0.59%)
After-Hours: 20:00
Beam Therapeutics Cash from Operations (TTM): -305.78M for March 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2023 | -305.78M |
December 31, 2022 | 22.53M |
September 30, 2022 | 93.55M |
June 30, 2022 | 171.05M |
March 31, 2022 | 190.80M |
December 31, 2021 | -66.27M |
September 30, 2021 | -92.40M |
Date | Value |
---|---|
June 30, 2021 | -116.62M |
March 31, 2021 | -106.93M |
December 31, 2020 | -95.74M |
September 30, 2020 | -89.24M |
June 30, 2020 | -85.02M |
March 31, 2020 | -73.54M |
December 31, 2019 | -72.00M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-305.78M
Minimum
Mar 2023
190.80M
Maximum
Mar 2022
-44.69M
Average
-79.28M
Median
Cash from Operations (TTM) Benchmarks
Twist Bioscience Corp | -133.75M |
Editas Medicine Inc | -163.89M |
Intellia Therapeutics Inc | -362.81M |
Cerus Corp | -12.66M |
Perspective Therapeutics Inc | -- |